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Tumour-associated isoenzymes of y-glutamyl transferase
in the serum ofpatients with hepatocellular carcinoma
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Departments ofMedicine and Medical Biochemistry, University of the Witwatersrand Medical School and
South African Institutefor Medical Research, Johannesburg, South Africa.
Summary Sera from 391 southern African Blacks with hepatocellular carcinoma, matched controls, patients
with other malignant tumours, and with various forms of hepatobiliary disease were fractionated by
polyacrylamide gradient gel electrophoresis to determine the prevalence of tumour-associated y-glutamyl
transferase isoenzymes in Black patients with hepatocellular carcinoma. One or more tumour-associated
isoenzymes (I', I" or II') were present in 58.6% of the patients with hepatocellular carcinoma: I' in 54.5%, I"
in 27.1%, and II' in 34%. These isoenzymes were detected in one patient with prostatic cancer, occasionally
in patients with acute viral hepatitis, but in no normal individuals. The presence of tumour-associated iso-
enzymes was not related to patient age, sex or hepatitis-B virus status or to the tumour burden. Isoenzymes
were present in 42 percent of hepatocellular carcinoma patients with a normal serum a-foetoprotein
concentration and in 50% of those with a non-diagnostic value. y-glutamyl transferase isoenzymes may be
supplementary to a-foetoprotein in the diagnosis of hepatocellular carcinoma.
Gamma-glutamyl transferase (EC 2.3.2.2) (y-GT)
activity is high in foetal liver (Albert et al., 1970;
Fiala et al., 1972), in experimental hepatocellular
carcinoma (HCC) tissue (Fiala et al., 1972; Fiala &
Fiala, 1973; Kalengayi et al., 1975), and in the
preneoplastic lesions which precede these tumours
(Kalengayi et al., 1975; Ohmori et al., 1981), but is
low in adult liver tissue (Albert et al., 1970; Fiala
et al., 1970). This exact parallel in behaviour with
a-foetoprotein (aFP), a known carcinoembryonic
glycoprotein and a useful serum marker of human
HCC (Kew & Newberne, 1982), suggested that y-GT
too might have carcinoembryonic characteristics,
and that a foetal isoenzyme might be produced and
secreted by human HCC tissue and serve as an
additional marker of this tumour. Indeed, tumour-
associated (or novel) isoenzymes of y-GT have
recently been demonstrated in the serum of a
proportion of Japanese patients with HCC (Kojima
et al., 1980; Sawabu et al., 1983). The purpose of
the present study was to determine the frequency
with which tumour-associated isoenzymes of y-GT
occur in HCC in another population which has a
high incidence of this tumour, namely southern
African Blacks, and to assess the diagnostic value
of these isoenzymes in comparison with cxFP.
Patients and methods
Sera from 391 southern African Blacks with
histologically-proved HCC were fractionated by
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polyacrylamide gradient gel electrophoresis to
determine the prevalence of tumour-associated
isoenzymes of y-GT. The patients studied ranged in
age from 13 to 87 years with a mean age of 45.2
years. Males constituted 86.5% of the cohort
studied. For the purpose of racial comparison, sera
from 22 caucasian patients with HCC were also
tested.
The following groups of subjects served as
controls: 80 apparently healthy age-, sex-, and
ethnically-matched individuals (including six in
whom the serum was concentrated three-fold using
polyethylene glycol); 46 patients with various
malignant tumours other than HCC with or
without hepatic metastases (arising from breast,
stomach, lung, ovary, pancreas, cervix, kidney,
prostrate, bladder, rectum or oesophagus;
teratocarcinoma, cholangiocarcinoma); 32 patients
with amoebic liver abscess; 22 patients with active
chronic hepatitis or cirrhosis; 29 patients with acute
viral hepatitis; and 28 patients with biliary
obstruction.
Sera were separated and stored at -20°C until
assayed. Electrophoretic separation of y-GT was
performed on Pharmacia polyacrylamide gradient
gel slabs (PAA4/30) using the Pharmacia Gel
Electrophoresis Apparatus GE-2/4 LS (Pharmacia
Fine Chemicals, Uppsala, Sweden) according to the
method of Kojima et al. (1980). The N-y-glutamyl-
oa-naphthylamide used in the substrate mixture and
the glycylglycine were obtained from Sigma
Chemical Co., St Louis, Mo. The gels were stained
with Fast Garnet GBC which was also obtained
from the Sigma Chemical Co. The Pharmacia Fine
Chemicals Electrophoresis Calibration Kit for
determination of high mol wt proteins, containing
albumin, lactic dehydrogenase, catalase, ferritin and
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thyroglobulin, together with bovine transferrin
(Sigma Chemical Co.) was used as a basis of
electrophoretic comparison after staining with
Coomassie Brilliant Blue R-250.
In sera from normal individuals up to 10 y-GT
fractions (I-X) are obtained. The electrophoretic
mobility of fraction I is comparable to transferrin,
that of fraction II to lactic dehydrogenase, that of
fraction III to catalase, that of fraction V to
ferritin, and that of fraction VIII to thyroglobulin.
The purified proteins used as markers have no
y-GT activity. Three tumour-associated (or novel)
fractions have been described in patients with
HCC: these are labelled I', I" and II' by Kojima et
al. (1980). Fraction I' migrates slightly slower than
fraction I, fraction I" slightly faster than fraction II,
and fraction II' bewteen fractions II and III (Figure
1).
The serum concentration of y-GT was determined
in the HCC patients on a Multistat III centrifugal
analyser using the Boehringer Mannheim Kit. No.
125954 with L-y-glutamyl-3-carboxy-4-nitroanilide
as the substrate. The enzyme activity was expressed
in international units per litre of serum at 37°C.
Serum aFP concentrations in the HCC patients
were measured by double-antibody radio-
immunoassay (Amersham Corp., Arlington
Heights, Ill.). The HCC patients' sera were also
tested for hepatitis-B virus surface antigen (HBsAg)
using a double-antibody radioimmunoassay (Ausria
II; Abbott Laboratories, North Chicago, Ill.).
The statistical validity of the findings was tested
using either the Chi square test with Yates'
modification for small numbers or an unpaired
Students' t test.
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Figure 1 Polyacrylamide gradient gel electrophoresis of
serum y-glutamyl transferase. Theisoenzymes which may
be present in normal serum or in patients with benign
hepatobiliary disease are indicated by the small Greek
numerals I to X; the position ofthe 3 tumour-associated
isoenzymes is alsoshown. A. Normal human serum. B-F.
Serum from patients with hepatocellular carcinoma
showing various combinations of the 3 tumour-specific
isoenzymes (in addition to normal fractions in some
patients).
Results
Hepatocellular carcinoma patients
Fraction I' was detected in 54.5% (213/391) of the
HCC patients, fraction I" in 27.1% (106/391), and
fraction II' in 34.0% (133/391). One or more of the
three tumour-associated isoenzymes was detected in
58.6% (229/391) of the HCC patients. The
prevalence of the various combinations of the
tumour-associated isoenzymes is shown in Table I.
Fraction I' was the most frequent of the single
fractions (75/86), and the simultaneous presence of
I', I" and II" among the combined patterns
(80/143).
Controls
Tumour-associated isoenzymes were not detected in
any of the 80 healthy controls, including the six in
whom the serum was concentrated, or in any of the
32 patients with amoebic liver abscess, the 28 with
biliary obstruction, or the 22 patients with chronic
active hepatitis or cirrhosis. One or more tumour-
associated fractions were occasionally found in the
other control groups (Table I). The one patient
with malignant disease to show these isoenzymes
had prostatic cancer complicated by skeletal but
not hepatic metastases.
Correlation with sex, age and race
Sex
The presence of tumour-associated y-GT
isoenzymes was not related to the sex of the
patients with HCC, males constituting 88.7% of the
patients with, and 83.3% of those without these
isoenzymes. There was also no difference with
regard to sex between patients having I', I" or II'
fractions, males constituting 88.8% of patients with
I' and I" and 87.3% of those with II'.
Age
There was no correlation between the presence of
tumour-associated y-GT isoenzymes and patient
age. The mean age (and s.d.) of the patients with
these isoenzymes was 44.6+ 14.7 years (range 17-
87) and those without isoenzymes 46.4+15.5 years
(range 13-78 years). Nor was there any difference
between the ages of the patients with I', I" or
II' (44.2+ 14.3; 43.8 + 14.6; 44.3 + 15.8 years,
respectively).
Race
One or more tumour-associated y-GT isoenzymes
were detected in 36.4% (8/22) of the caucasian
patients with HCC. This difference from the Black
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Table I Prevalences of tumour-associated isoenzymes of -glutamyl transferase in patients with hepatocellular
carcinoma and in various control subjects.
Single pattern Combinedpattern
1' 1" 11' J'+J" J'+11" J"+JJ' J'+J"+JJ"
Hepatocellular carcinoma 19.2* 0 2.8 5.4 9.5 1.3 20.5
(75/391) (0/391) (11/391) (21/391) (37/391) (5/391) (80/391)
Other tumours 0 0 0 0 2.2 0 0
(1/46)
Acute viral hepatitis 0 0 10.3 0 0 0 0
(3/29)
*Values are percentages; fractions in parentheses.
patients does not reach statistical significance. The
same applies for each of the individual isoenzymes:
I' 31.8% (7/22); I" 9.1% (2/22); II' 22.7% (5/22). It
is, of course, possible that with a larger group of
caucasian patients the difference might reach
statistical significance.
Relationship between y-GT isoenzymes and y-GT
Serum y-GT levels were raised (>50U1- in
normal men and 35Ul-1 in normal women) in 95%
(359/378) of the HCC patients; values ranged up to
1617 UI-1. HCC patients with one or more
tumour-associated isoenzymes were more likely to
have a raised serum y-GT value (99.1%; 221/223)
than those without isoenzymes (89.0%; 138/155;
P<0.001). Patients having all 3 isoenzymes
invariably had a raised serum y-GT concentration.
There was no difference in the percentage of
patients with an elevated y-GT level between those
with I' (99.5%), I" (100%) and II' (99.2%). The
mean serum y-GT concentration was significantly
higher (346+220UI 1) in patients with than in
those without (261+228UP-1) (P<0.0005) tumour-
associated y-GT isoenzymes. There was no
significant difference between the serum values of
patients having all 3 isoenzymes and those having
one or two isoenzymes. Nor was there any
difference between those having I' (351 +223 Ul 1),
I" (357+186Ul-1) or II'(349+ 187Ul-1).
Serum axFP concentrations were raised
(>lOngml-1) in 91.6% (358/391) of the HCC
patients. Concentrations ranged up to
1,828,026ngml-1. Values greater than 500ngml -1,
considered virtually diagnostic of HCC, were
present in 75.2 % (294/391) of the patients: 16.9%
(66/391) of the patients had values in the non-
diagnostic range (10-500ngml-1). Patients with
one or more tumour-associated y-GT isoenzymes
were more likely to have a raised aXFP value (94.3%;
216/229) thanthosewithout theseisoenzymes (88.3%;
143/162) (P<0.05)). There was no difference in
the likelihood of having a raised ocFP level between
patients with I' (93.9%), I" (97.2%) and II' (97%).
Serum xFP concentrations were not significantly
different in patients with (103,203+217,060ngml 1)
and without (115,962 +292,232ngml-1) iso-
enzymes (P>0.05).
Ofthe 33 patients with a normnal serum aFP value,
tumour-associated y-GT isoenzymes were detected
in 14 (42.4%). In practice, therefore, if serum from
patients with HCC was tested for both
AFP and y-GT isoenzymes 95.2% of the patients
would have a marker of HCC (either a raised
serum a-FP value or a tumour-associated iso-
enzyme of y-GT) whereas 91.6% of the patients
would have a marker (raised serum aIFP level) if
y-GT isoenzymes were not measured. Of the 66
patients in the non-diagnostic cxFP range (10-
500ngml-1) 33 (50.0%) had one or more y-GT
isoenzymes. In practice, if y-GT isoenzymes were
used together with aFP determination in the
diagnosis of HCC, it would then be possible to
reduce the number of patients with a non-
diagnostic aFP value from 16.9 to 8.4% i.e. only
8.4% of the patients would have neither an
isoenzyme of y-GT nor a diagnostic level of aFP
and hence no marker of HCC.
Relation between y-GT isoenzymes and HBsAg
No correlation could be demonstrated between the
presence of tumour-associated y-GT isoenzymes
and HBsAg, 46.5% (101/217) of the patients with
one or more isoenzymes and 42.0% (58/138) of
those without isoenzymes being HBsAg-positive.
There was no difference between patients with I', I"
and II' in respect to HBsAg-positivity (47.5, 47.0
and 44.0% respectively).
Relation between y-GT isoenzymes and tumour
burden
No correlation could be demonstrated between the
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and the extent of the tumour burden (tumour size
as judged by isotopic, ultrasonographic or
computed tomographic imaging techniques, and
extent of metastatic spread) in individual patients.
These enzymes are of no particular value in the
detection of small (and hence resectable) tumours.
Discussion
Although aFP is a most useful marker of HCC,
both "false-negative" and "false-positive" results
occur (Kew & Newberne, 1982). Even with a very
senstitive radioimmunoassay, approximately 8% of
patients in high incidence areas of the tumour have
values in the normal range, and in low incidence
regions this figure may be as high as 30%. Slightly
raised serum values (up to 500ngml-1) occur in
various forms of benign liver disease including
acute hepatitis, active chronic hepatitis and
cirrhosis. Elevetated levels may also be seen with
tumours of entodermal origin and the rare
embryonal teratocarcinomas of gonadal origin.
Alternative or additional markers having no 'false-
negative' or 'false-positive' results or else being
present when xFP is either normal or is present in
the non-diagnostic range, are still being sought.
Studies in Japanese patients have suggested that
novel 'tumour-associated' isoenzymes of y-GT
might serve as a marker of HCC (Kojima et al.,
1980; Sawabu et al., 1983).
The present investigation has shown a virtually
identical prevalence of tumour-associated y-GT
isoenzymes in another population with a high
incidence of HCC but differing in several respects
from Japanese patients, namely southern African
Blacks. The prevalence of tumour-associated y-GT
isoenzymes has not yet been documented in any
population with a low incidence of HCC. A
comparison between Black and Caucasian patients
was therefore attempted in the present study.
Although the prevalence of the isoenzymes was less
in Caucasian patients, the number of the latter was
small and the differences did not reach statistical
significance.
Tumour-associated y-GT isoenzymes are not
present sufficiently often in patients with HCC for
them to be superior to aFP as a marker of this
tumour. However, they might still be useful
diagnostically if they were detected in patients
having a normal cxFP value or one in the non-
diagnostic range. Unfortunately, the isoenzymes
tended to have a directly proportional rather than
an inversely proportional relationship with aFP:
y-GT isoenzymes were present in less than one-half
of the patients with normal or non-diagnostic
cxFP values. Nevertheless, they may be of some
diagno' ic value when used in conjunction with
cxFP estimation. Unlike aFP, which is related to both
the age and the sex of HCC patients (Kew &
Newberne, 1982), y-GT isoenzymes were not age-
or sex-related. It might be argued, therefore, that
y-GT isoenzymes may be somewhat more useful
diagnostically in elderly patients, especially females,
in whom aFP is less likely to be elevated. y-GT
isoenzymes were also not related to the aetiology of
the tumour, insofar that they did not correlate with
the presence or absence of HBs antigenemia. y-GT
isoenzymes are also of no particular value in the
early diagnosis of HCC.
The serum y-GT concentration was raised in
95% of our patients. Tumour-associated iso-
enzymes were shown to contribute to the serum
value in that patients with one or more of these
isoenzymes had significantly higher levels. However,
other factors also play a role because the serum
values were raised even in the absence of the
isonzymes. Only 1% of patients with tumour-
associated y-GT isoenzymes had a normal serum
y-GT value. In practice, therefore, tumour-associated
isoenzymes are very unlikely to be present in
patients with HCC if the serum y-GT concentration
is not raised.
Although tumour-associated y-GT isoenzymes
were not found in healthy Blacks (nor previously in
healthy Japanese (Kojima et al., 1980)), they were
present in a single patient with malignant disease,
and in three patients with acute viral hepatitis.
y-GT is normally present in many tissues but
particularly the pancreas and kidney (Albert et al.,
1961), and it is therefore not surprising that
tumour-associated isoenzymes are occasionally
encountered in patients with various forms of
malignancy (Jaken & Mason, 1978). The enzyme is
present in prostatic tissue (Albert et al., 1964;
Rosalki & Rowe, 1973), which would explain the
single patient who belonged in this category in our
series who had a prostatic carcinoma. The finding
of tumour-associated bands in an occasional patient
with acute hepatitis by ourselves and by Kojima et
al. (1980) or chronic hepatic parenchymal disease
by the latter workers is less easy to explain. There
is, however, an analogy with the raised levels of
aFP which may occur in the same conditions. The
latter has been attributed to production of aiFP by
regenerating hepatocytes (Kew & Newberne, 1982),
and perhaps the same applies to y-GT isoenzymes.
One explanation for the difference in
electrophoretic mobility of the tumour-associated
y-GT isoenzymes is that they may result from
differences in sialic acid content. A sialic acid-rich
foetal type y-GT has been detected in un-
differentiated cryptal cells, and in the foetal small
intestine and liver (Knottgen et al., 1976). This
suggests that y-GT, like acFP, has carcinoembryonic
characteristics. An alternative explanation for theSPECIFIC y-GT ISOENZYMES IN HEPATOMA 455
tumour-associated bands is that they are formed
artifactually by combining with lipoprotein or
glycoprotein in the serum (Freise et al., 1976).
ThisworkwassupportedinpartbygrantsfromtheNational
Cancer Association of South Africa and the South African
Chamber of Mines.
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